Abstract
Interferon-alpha therapy has proved effective for up to 40% of patients with adult-acquired chronic hepatitis B virus (HBV) infection and for 20-25% of those with chronic hepatitis C virus (HCV) infection. Nucleoside analogues, such as lamivudine and famciclovir, are showing promise as antiviral agents for chronic HBV and the combination of interferon-alpha and ribavirin is proving to be successful therapy for 40-50% of patients with chronic HCV. In this article we review current therapy and discuss future strategies of the therapy of chronic viral hepatitis.
MeSH terms
-
2-Aminopurine / analogs & derivatives
-
2-Aminopurine / therapeutic use
-
Animals
-
Antimetabolites / therapeutic use
-
Antiviral Agents / therapeutic use*
-
Carcinoma, Hepatocellular / etiology
-
Carcinoma, Hepatocellular / pathology
-
Carcinoma, Hepatocellular / prevention & control
-
Disease Models, Animal
-
Drug Therapy, Combination
-
Ducks
-
Famciclovir
-
Female
-
Hepatitis B, Chronic / drug therapy
-
Hepatitis B, Chronic / therapy*
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / therapy*
-
Hepatitis, Animal / virology
-
Humans
-
Immunologic Factors / therapeutic use*
-
Interferon-alpha / therapeutic use
-
Lamivudine / therapeutic use
-
Liver Cirrhosis / etiology
-
Liver Cirrhosis / prevention & control
-
Liver Neoplasms / etiology
-
Liver Neoplasms / pathology
-
Liver Neoplasms / prevention & control
-
Male
-
Marmota
-
Poultry Diseases / virology
-
Randomized Controlled Trials as Topic
-
Reverse Transcriptase Inhibitors / therapeutic use
-
Tumor Cells, Cultured
Substances
-
Antimetabolites
-
Antiviral Agents
-
Immunologic Factors
-
Interferon-alpha
-
Reverse Transcriptase Inhibitors
-
Lamivudine
-
2-Aminopurine
-
Famciclovir